HBV genotype B is associated with better response to interferon therapy in HBeAg( + ) chronic hepatitis than genotype C
Chun Tao Wai, Chi‐Jen Chu, Munira Hussain, Anna S. F. Lok – 7 March 2007 – Hepatitis B virus (HBV) genotype and precore/core promoter mutations have been implicated in spontaneous and interferon alfa (IFN‐α)—related hepatitis B e antigen (HBeAg) seroconversion. We performed a retrospective analysis of a previously reported randomized controlled trial to determine the effects of HBV genotype and precore/core promoter mutations on IFN‐α response in patients with HBeAg‐positive chronic hepatitis. Clinical data and stored sera from 109 (95%) patients in the original trial were analyzed.